
Sarepta Therapeutics (SRPT) Stock Forecast & Price Target
Sarepta Therapeutics (SRPT) Analyst Ratings
Bulls say
Sarepta Therapeutics is viewed positively because its core PMO franchise remains resilient, with 3Q PMO product revenue of $240.3M beating expectations and helping support cash flow, while total net product revenue guidance was narrowed to $1.25B-$1.3B on improved underlying performance. The Elevidys story also remains constructive, as 3Q U.S. revenue of $83.5M met Street expectations and interim ENDURE data showed no cases of ALI among 11 patients on prophylactic sirolimus, while exploratory PRO data suggested better mobility preservation versus external controls. In addition, lower-than-expected R&D spend at $82M, manageable SG&A of $118M, and the $39M patent settlement reduce operational and legal uncertainty, even as competition and regulatory review remain key watch items.
Bears say
Sarepta Therapeutics is facing a fragile fundamentals story because Elevidys sales of $83.5M in 3Q aligned with a “downquarter” but still suggest a predictable, and potentially flat, trajectory rather than the inflection needed to reaccelerate growth. The write-up highlights unresolved efficacy questions from non-significant randomized NSAA results, weaker-than-expected external-control support, and a sub-$400M peak opportunity by ’28, while safety concerns remain material with 7-9% serious ALI rates and prior fatal liver failure in non-ambulatory patients. With the PMO franchise also exposed to regulatory, clinical, and competitive risk, the company may struggle to generate enough durable cash flow to meet debt and partnership obligations.
This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction
Start investing in Sarepta Therapeutics (SRPT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Sarepta Therapeutics (SRPT) Forecast
Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction
Start investing in Sarepta Therapeutics (SRPT)
Order type
Buy in
Order amount
Est. shares
0 shares